Merck Acquires Cancer Drug Rights

Apr 17, 2012, 04:00 AM by Michael Croft

Reuters | Merck has acquired the rights to an Endocyte cancer drug candidate for $120 million and up to $880 million in milestone payments.

April 17, 2012 | Merck has acquired the rights to an Endocyte cancer drug candidate for $120 million and up to $880 million in milestone payments, the companies announced yesterday. Endocyte shares rose 101% after the announcement. Reuters